CN111480849B - Composite probiotic microcapsule powder for mother emulsification and preparation method and application thereof - Google Patents
Composite probiotic microcapsule powder for mother emulsification and preparation method and application thereof Download PDFInfo
- Publication number
- CN111480849B CN111480849B CN202010258804.7A CN202010258804A CN111480849B CN 111480849 B CN111480849 B CN 111480849B CN 202010258804 A CN202010258804 A CN 202010258804A CN 111480849 B CN111480849 B CN 111480849B
- Authority
- CN
- China
- Prior art keywords
- powder
- bacterial
- composite probiotic
- parts
- mother
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 102
- 239000006041 probiotic Substances 0.000 title claims abstract description 82
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 82
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 61
- 239000002131 composite material Substances 0.000 title claims abstract description 54
- 239000003094 microcapsule Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000004945 emulsification Methods 0.000 title claims abstract description 11
- 230000001580 bacterial effect Effects 0.000 claims abstract description 82
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 36
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 35
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 23
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 23
- 241000186315 Lactobacillus paracasei N1115 Species 0.000 claims abstract description 21
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 21
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 21
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 21
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 16
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims abstract description 14
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims abstract description 14
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000020256 human milk Nutrition 0.000 claims abstract description 13
- 210000004251 human milk Anatomy 0.000 claims abstract description 13
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000839 emulsion Substances 0.000 claims abstract description 8
- 235000011187 glycerol Nutrition 0.000 claims abstract description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108010010803 Gelatin Proteins 0.000 claims abstract description 6
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 6
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 6
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 6
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 6
- 239000008273 gelatin Substances 0.000 claims abstract description 6
- 229920000159 gelatin Polymers 0.000 claims abstract description 6
- 235000019322 gelatine Nutrition 0.000 claims abstract description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 6
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 6
- 239000000661 sodium alginate Substances 0.000 claims abstract description 6
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 6
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 6
- 235000021119 whey protein Nutrition 0.000 claims abstract description 6
- 235000013350 formula milk Nutrition 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 239000002504 physiological saline solution Substances 0.000 claims description 12
- 239000003223 protective agent Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000010802 sludge Substances 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 36
- 241000894006 Bacteria Species 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000186000 Bifidobacterium Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003833 bile salt Substances 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 230000002906 microbiologic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 239000004594 Masterbatch (MB) Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- -1 citric acid diamine Chemical class 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 101150099542 tuf gene Proteins 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a breast-milk compound probiotics microcapsule powder, which belongs to the field of foods and comprises bifidobacterium animalis subspecies i797, lactobacillus paracasei N1115, lactobacillus plantarum N3117 and streptococcus thermophilus JMCC0003; the raw materials for preparing the active ingredients comprise soybean oligosaccharide, galactooligosaccharide, 3' -sialyllactose, maltodextrin, whey protein powder, sodium alginate, gelatin and glycerol; the invention also discloses a preparation method of the composite probiotic microcapsule powder for mother emulsification, which comprises the steps of preparing the bacterial powder, the composite probiotic microcapsule powder and the like; the invention also discloses application of the composite probiotic microcapsule powder which is eaten singly or mixed with infant formula to eat mother emulsion. The product of the invention can promote beneficial bacteria field planting, strengthen the stability of infant intestinal flora field planting, solve infant intestinal flora field planting fluctuation caused by delivery mode difference, and is suitable for infants.
Description
Technical Field
The invention belongs to the field of foods, and relates to composite probiotic microcapsule powder, in particular to breast-milk composite probiotic microcapsule powder, and a preparation method and application thereof.
Background
Since the metabolic system of the infant is not yet developed completely, special requirements are made of nutrition intake, and breast milk is the most natural and most suitable food for the infant in the growth process. The World Health Organization (WHO) states that infants should be fed pure breast milk 6 months before life to achieve optimal levels of growth and health. The breast milk contains rich nutrients including lactose, fat, protein, vitamins, minerals, oligosaccharide, immunoglobulin, etc. In addition, breast feeding is carried out within 1 hour after birth, so that the neonate can be effectively protected from disease infection.
Furthermore, breast milk also transports bacteria from the mother, which is one of the main sources of infant gastrointestinal flora. The study shows that the colostrum contains abundant microorganisms, and the establishment of intestinal flora and the development and maturation of immune function of infants can be promoted by performing mother-infant vertical transmission through breast feeding.
The intestinal flora of infants is established from the beginning of life and interacts with the development of the nervous system, continuing to adulthood. The intestinal flora development of infants is divided into 3 stages, the development stage is less than or equal to 14 months, and bifidobacteria are dominant; 15-30 months is a transitional period, so that the flora diversity is increased; the stationary phase is more than or equal to 31 months, and the firmicutes are dominant.
However, in addition to breast feeding, the establishment and stabilization of the intestinal flora of infants is also affected by a number of factors, such as delivery pattern, genetic factors, eating habits, etc. Studies have shown that the initial colonisation of the intestinal flora of a syngeneic infant is largely determined by the abundance of microorganisms that the infant contacts from the mother's vagina, skin, etc., whereas the intestinal flora of a caesarean infant is largely dependent on the external environment and microorganisms on the mother's skin, and differs significantly from the intestinal flora of a syngeneic infant.
In addition, in the prior art, no probiotic product which can be added to infant formula milk powder in an auxiliary way is available, so that infant intestinal flora field planting fluctuation caused by delivery mode difference is improved, and the stability of infant intestinal flora field planting is enhanced.
Disclosure of Invention
The invention aims to provide a composite probiotic microcapsule powder for mother emulsification so as to solve the problem of infant intestinal flora field planting fluctuation caused by delivery mode difference;
the invention also aims to provide a preparation method of the composite probiotic microcapsule powder for mother emulsification;
it is also an object of the present invention to provide the use of the above-described parent emulsified composite probiotic microcapsule powder.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the raw materials for preparing the composite probiotic microcapsule powder for the mother emulsion comprise bifidobacterium animalis subspecies i797, lactobacillus paracasei N1115, lactobacillus plantarum N3117 and streptococcus thermophilus JMCC0003.
The bifidobacterium animalis subspecies lactis i797 used in the inventionBifidobacterium animalis subsp. lactisi797 8 months and 20 days in 2019, china general microbiological culture Collection center (national patent office designation patent microbiological collection center), accession number: CGMCC No.18403;
lactobacillus paracasei N1115%Lactobacillus paracaseiN1115), 3 months and 17 days in 2011, the China general microbiological culture Collection center (national patent office designation patent microbiological collection center), accession number: CGMCC No.4691, which is disclosed for the first time in Chinese invention patent with patent number 201110357058.8;
lactobacillus plantarum N3117%Lactobacillus plantarumN3117) has been 12 in 2014For 5 days, china general microbiological culture Collection center (national patent office designation patent microbiological collection center) with accession number: CGMCC No.10133, which is disclosed for the first time in Chinese invention patent with the patent number of 201510936243.0;
streptococcus thermophilus JMCC 0003%Streptococcus thermophilusJMCC 0003) has been deposited at 10/15 of 2012 in the chinese microbiological bacterial strain deposit management committee common microbiological center (national patent office designation patent microbiological deposit center) at hospital No. 3 of north chen west way No.1, the region of north dynia in beijing, deposit number: CGMCC No.6674, which is disclosed for the first time in the Chinese invention patent with the patent number of 201510938581.8.
A kind of breast milk compound probiotics microcapsule powder, it contains four probiotics, namely animal bifidobacterium milk subspecies i797, lactobacillus paracasei N1115, lactobacillus plantarum N3117 and streptococcus thermophilus JMCC0003;
the raw materials for preparing the effective components of the breast-milk-based composite probiotic microcapsule powder comprise, by weight, 1-5 parts of soybean oligosaccharide, 5-10 parts of galactooligosaccharide, 0.1-2 parts of 3' -sialyllactose, 5-15 parts of maltodextrin, 5-10 parts of whey protein powder, 1-3 parts of sodium alginate, 1-5 parts of gelatin and 0.1-3 parts of glycerin.
As a limitation of the invention, the raw materials for preparing the active ingredients of the master emulsified composite probiotic microcapsule powder also comprise 1 to 10 parts by weight of bifidobacterium animalis subspecies i797 bacterial mud, 0.5 to 5 parts by weight of lactobacillus paracasei N1115 bacterial mud, 0.5 to 5 parts by weight of lactobacillus plantarum N3117 bacterial mud and 0.5 to 5 parts by weight of streptococcus thermophilus JMCC0003 bacterial mud, wherein the four bacterial mud respectively contain corresponding probiotics not less than 1 multiplied by 10 11 CFU/g。
As another limitation of the invention, the breast-milk-based composite probiotic microcapsule powder contains bifidobacterium animalis subspecies i797 which is more than or equal to 1 multiplied by 10 10 CFU/g, lactobacillus paracasei N1115 is more than or equal to 1X 10 10 CFU/g, lactobacillus plantarum N3117 is more than or equal to 1X 10 10 CFU/g and streptococcus thermophilus JCCC 0003 is more than or equal to 1 multiplied by 10 10 CFU/g。
The invention also provides a preparation method of the master-emulsified composite probiotic microcapsule powder, which comprises the following steps in sequence:
1) Preparation of bacterial powder
The preparation method comprises the steps of preparing bifidobacterium animalis subspecies i797 powder, lactobacillus paracasei N1115 powder, lactobacillus plantarum N3117 powder and streptococcus thermophilus JMCC0003 powder, wherein the powder is prepared by the following steps of:
11 Mixing maltodextrin, whey protein powder, sodium alginate, gelatin and glycerol to obtain a mixture A;
12 Adding the mixture A into purified water, hydrating and dissolving, homogenizing, and sterilizing to obtain a sterile protective agent B;
13 Taking bacterial mud of corresponding probiotics, respectively and uniformly mixing with the aseptic protective agent B, freeze-drying, crushing and sieving to obtain bacterial powder of the corresponding probiotics;
2) Preparing composite probiotic microcapsule powder in a mother emulsion:
and uniformly mixing the bacterial powder of the four probiotics, namely, the bifidobacterium animalis subspecies i797 bacterial powder, the lactobacillus paracasei N1115 bacterial powder, the lactobacillus plantarum N3117 bacterial powder and the streptococcus thermophilus JMCC0003 bacterial powder, with soybean oligosaccharide, galactooligosaccharide and 3' -sialyllactose to obtain the composite probiotic microcapsule powder for mother emulsification.
As a limitation of the invention, each bacterial sludge is fermented by corresponding probiotics until the bacterial count is more than or equal to 1 multiplied by 10 11 After CFU/mL, the bacterial liquid is collected and centrifuged to obtain the bacterial liquid.
As a further limitation of the present invention, each bacterial sludge is washed and centrifuged after being produced.
As a further limitation of the present invention, the washing process is washing with sterile physiological saline 1-2 times;
the fermentation temperature is 30-42 ℃, and the fermentation time is 36-48 h;
the rotational speed of the centrifugation is 4000-6000 rpm, and the time of the centrifugation is 8-15 min.
As another limitation of the present invention, in step 1), the temperature of the hydration dissolution is 35-40 ℃;
the homogenizing temperature is 60-65 ℃;
the sterilization is carried out at 110-121 ℃ for 20-25min;
in the step 2), the mixing is carried out for 10-15min.
As a third limitation of the present invention, in step 1), the weight ratio of each bacterial sludge to the sterility protectant B is 1:1-20;
the grain diameter of each bacterial powder is less than or equal to 40 meshes;
in the step 2), the viable count of each probiotic is maintained to be more than or equal to 1 multiplied by 10 during the mixing process 10 CFU/g。
The invention also provides an application of the mother emulsified composite probiotic microcapsule powder, and the mother emulsified composite probiotic microcapsule powder can be used for being eaten independently or being mixed with infant formula milk powder.
The bifidobacterium animalis subspecies i797 is separated and screened from faeces of breast-fed infants or young children, has good intestinal tract regulating effect, can regulate intestinal flora balance and improve faeces characteristics;
the 16SrRNA sequence of the bifidobacterium animalis subspecies i797 strain is as follows:
ACGGCTCCCCCACAAGGGTCGGGCCACCGGCTTCGGGTGCTACCCACTTTCATGACTTGACGGGCGGTGTGTACAAGGCCCGGGAACGCATTCACCGCGGCGTTGCTGATCCGCGATTACTAGCGACTCCGCCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGACCGGTTTTCAGCGATCCGCCCCACGTCACCGTGTCGCACCGCGTTGTACCGGCCATTGTAGCATGCGTGAAGCCCTGGACGTAAGGGGCATGATGATCTGACGTCATCCCCACCTTCCTCCGAGTTGACCCCGGCGGTCCCACATGAGTTCCCGGCATCACCCGCTGGCAACATGCGGCGAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACGACCATGCACCACCTGTGAACCGGCCCCGAAGGGAAACCGTGTCTCCACGGCGATCCGGCACATGTCAAGCCCAGGTAAGGTTCTTCGCGTTGCATCGAATTAATCCGCATGCTCCGCCGCTTGTGCGGGCCCCCGTCAATTTCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCCAGGCGGGATGCTTAACGCGTTGGCTCCGACACGGGACCCGTGGAAAGGGCCCCACATCCAGCATCCACCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTGACGGCCCAGAGACCTGCCTTCGCCATTGGTGTTCTTCCCGATATCTACACATTCCACCGTTACACCGGGAATTCCAGTCTCCCCTACCGCACTCCAGCCCGCCCGTACCCGGCGCAGATCCACCGTTAGGCGATGGACTTTCACACCGGACGCGACGAACCGCCTACGAGCCCTTTACGCCCAATAAATCCGGATAACGCTCGCACCCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGTGCTTATTCGAACAATCCACTCAACACGGCCGAAACCGTGCCTTGCCCTTGAACAAAAGCGGTTTACAACCCGAAGGCCTCCATCCCGCACGCGGCGTCGCTGCATCAGGCTTGCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTATCTCAGTCCCAATGTGGCCGGTCACCCTCTCAGGCCGGCTACCCGTCAACGCCTTGGTGGGCCATCACCCCGCCAACAAGCTGATAGGACGCGACCCCATCCCATGCCGCAAAAGCATTTCCCACCCCACCATGCGATGGAGCGGAGCATCCGGTATTACCACCCGTTTCCAGGAGCTATTCCGGTGCACAGGGCAGGTTGGTCACGCATTACTCACCCGTTCGCCACTCTCACCCGACAGCAAGCTGCCAGGGATCCCGTTCGACTGCATGTGTAAG。
the tuf gene sequence is as follows:
GGATCTCGATGAGAGCAGCGTGGTATCACCATCAACATTGCCCACATCGAGTACCAGACGGCCAAGCGTCACTACGCCCACGTCGACTGCCCGGGCCACGCCGACTTCGTGAAGAACATGATCACCGGCGCTGCCCAGATGGATGGCGCCATCCTCGTTGTGGCCGCCACCGACGGCCCGATGGCCCAGACCCGCGAGCACGTGCTGCTCGCCCGTCAGGTCGGCGTCCCGAAGATCCTCGTCGCTCTGAACAAGTGCGATATGGTCGATGACGAAGAGCTCATCGAGCTCGTCGAAGAAGAGGTCCGCGACCTCCTCGACGAGAACGGCTTCGACCGCGACTGCCCGGTCGTGCACACCTCCGCTTACGGCGCTCTGCATGACGACGCTCCCGGATCACGACAAGTGGGTTGCCACCATCAAGGAGCTCATGGACGACGTCGACGAGTACATCCCGACCCCGGTCCACGACCTCGACAAGCCGTTCCTGATGCCGATCGAGGACGTCTTCACCATCTCCGGCCGTGGCACCGTCGTCACCGGTCGTGTCGAGCGCGGCAAGCTGCCGATCAACACGAACGTCGAGATCGTCGGCATCCGCCCGACCCAGACCACCACCGTCACCTCCATCGAGACCTTCCACAAGCAGATGGATGAGTGCGAGGCCGGCGACAACACCGGTCTGCTGCTCCGCGGCATCAACCGCACCGACGTCGAGCGTGGCCAGGTCGTGGCTGCTCCGGGTTCGGTCACCCCGCACACCAAGTTCGAAGGCGAAGTCTACGTCCTTACCAAGGATGAGGGCGGCCGTCACTCGCCGTTCTTCTCGAACTACCGTCCGCAGTTCTACTTCCGCACCACCGACGTCACCGGCGTCATCACGCTGCCGGAAGGCGTCGAGATGGTTCAGCCTGGCGATCACGCGACCTTCACGGTTGAGCTGATCCAGCCGATCGCTATGGAAGAGGGCTTCACCTTCCCAGTGCTTGAAGGC。
compared with the prior art, the invention has the following advantages:
the invention relates to a composite probiotic microcapsule powder for female emulsification, which is prepared according to microbial diversity variation in breast milk, and contains a plurality of probiotics, wherein bifidobacterium animalis subspecies i797 are taken as a main material, lactobacillus paracasei N1115, lactobacillus plantarum N3117 and streptococcus thermophilus JMCC0003 are added at the same time, beneficial bacteria field planting is promoted by optimizing the proportion, infant intestinal flora field planting fluctuation caused by delivery mode difference is improved, and the stability of infant intestinal flora field planting is enhanced;
the soybean oligosaccharide is a total name of soluble sugar in soybean, and accounts for about 10% of the content of mature soybean, and consists of sucrose, raffinose and stachyose. Soy oligosaccharides are not digested by the human body and some harmful bacteria, but can be utilized by bifidobacteria. The addition of soy oligosaccharide helps the bifidobacteria to proliferate in the human intestinal tract;
3' sialyllactose is a sialylated oligosaccharide in breast milk, and is present in an amount of about 0.1-0.3 g/L in breast milk and remains relatively stable throughout the lactation period. The 3' sialyllactose can support the growth of probiotics such as bifidobacteria in the intestinal tract, has the characteristic of resisting inflammation, can reduce the attachment of conditional pathogenic bacteria in the intestinal tract, and further promotes the development of the nervous system of the infant through the intestinal-brain axis.
The mother emulsified composite probiotic microcapsule powder is suitable for infants, and can improve infant intestinal flora field planting fluctuation caused by delivery mode difference.
Description of the drawings:
FIG. 1 is a graph showing the effect of a bacterial suspension of a complex probiotic mixture on intestinal barrier function according to example 8 of the present invention;
FIG. 2 is a graph showing the effect of the oligosaccharide mixture on the proliferation of Bifidobacterium enterica in example 9 of the present invention;
FIG. 3 is a diagram showing the constitution change of a newborn mouse in example 10 of the present invention;
FIG. 4 is a graph showing the intestinal bifidobacterium change in the newborn mice in example 10 of the present invention.
Detailed Description
The invention is further illustrated by the following specific examples, it being understood that the examples are presented by way of illustration only and are not intended to be limiting.
Examples 1-6 composite probiotic microcapsule powder mother-emulsified and preparation method thereof
Examples 1-6 are respectively mother emulsified composite probiotic microcapsule powders, and the raw materials for preparing the active ingredients are the same, except that the amounts of the raw materials in different examples are different, and the specific details are shown in Table 1:
table 1 raw material ratio list
The following is a preparation method of the composite probiotic microcapsule powder of the mother emulsion in example 1, which comprises the following steps in sequence according to the raw material dosage in example 1:
1) Preparing probiotic powder:
the preparation method comprises the steps of preparing bifidobacterium animalis subspecies i797 powder, lactobacillus paracasei N1115 powder, lactobacillus plantarum N3117 powder and streptococcus thermophilus JMCC0003 powder, wherein the powder is prepared by the following steps of:
115 kg of maltodextrin, 10kg of whey protein powder, 3kg of sodium alginate, 2kg of gelatin and 1kg of glycerol are weighed and stirred at room temperature for 10min until the mixture is fully and uniformly mixed to prepare a mixture A;
adding the mixture A into 29L of purified water, dissolving at 35 ℃ by hydration, heating to 60 ℃, keeping the temperature at 60 ℃ for homogenization, and sterilizing at 110 ℃ for 20min to obtain 50kg of aseptic protective agent B;
weighing 1kg of bifidobacterium animalis subspecies i797 bacterial mud and 20kg of aseptic protective agent B, stirring at room temperature for 20min, uniformly mixing, freeze-drying, crushing, and sieving with a 40-mesh sieve to obtain 1kg of bifidobacterium animalis subspecies i797 bacterial powder with the particle size less than or equal to 40 meshes;
weighing 0.5kg of lactobacillus paracasei N1115 bacterial mud and 10kg of aseptic protective agent B, stirring at room temperature for 20min, uniformly mixing, freeze-drying, crushing, and sieving with a 40-mesh sieve to obtain 0.5kg of lactobacillus paracasei N1115 bacterial powder with the particle size less than or equal to 40 meshes;
weighing 0.5kg of lactobacillus plantarum N3117 bacterial mud and 10kg of aseptic protective agent B, stirring at room temperature for 20min, uniformly mixing, freeze-drying, crushing, and sieving with a 40-mesh sieve to obtain 0.5kg of lactobacillus plantarum N3117 bacterial powder with particle size less than or equal to 40 meshes;
weighing 0.5kg of streptococcus thermophilus JCCC 0003 bacterial mud and 10kg of aseptic protective agent B, stirring at room temperature for 20min, uniformly mixing, freeze-drying, crushing, and sieving with a 40-mesh sieve to obtain 0.5kg of streptococcus thermophilus JCCC 0003 bacterial powder with the particle size less than or equal to 40 meshes.
The preparation process of the bacterial mud comprises the following steps:
placing animal Bifidobacterium lactis subspecies i797 in a fermenter, fermenting at 35deg.C for 40 hr, and culturing until the bacterial count is not less than 1×10 11 Collecting bacterial liquid by CFU/mL, centrifuging at room temperature and 5000rpm for 10min to obtain bacterial cells, washing with sterile physiological saline of equal bacterial liquid amount for 2 times, centrifuging at room temperature and 5000rpm for 10min to obtain lactobacillus bifidus subspecies i797 bacterial mud with viable count of 1×10 11 CFU/g；
Placing Lactobacillus paracasei N1115 in a fermenter, fermenting at 35deg.C for 40 hr until the bacterial count is not less than 1×10 11 Collecting bacterial liquid by CFU/mL, centrifuging at room temperature and 5000rpm for 10min to obtain bacterial cells, washing with sterile physiological saline of equal bacterial liquid amount for 2 times, centrifuging at room temperature and 5000rpm for 10min to obtain lactobacillus paracasei N1115 bacterial mud, and collecting viable count of 1×10 11 CFU/g；
Placing Lactobacillus plantarum N3117 in a fermenter, fermenting at 35deg.C for 40 hr until the bacterial count is not less than 1×10 11 Collecting bacterial liquid by CFU/mL, centrifuging at room temperature and 5000rpm for 10min to obtain bacterial cells, washing with sterile physiological saline of equal bacterial liquid amount for 2 times, centrifuging at room temperature and 5000rpm for 10min to obtain lactobacillus plantarum N3117 bacterial mud, and collecting bacterial count of 1×10 11 CFU/g；
Placing Streptococcus thermophilus JMCC0003 in a fermenter, fermenting at 35deg.C for 40 hr until the bacterial count is not less than 1×10 11 Collecting bacterial liquid by CFU/mL, centrifuging at room temperature and 5000rpm for 10min to obtain bacterial cells, washing with sterile physiological saline of equal bacterial liquid amount for 2 times, centrifuging at room temperature and 5000rpm for 10min to obtain Streptococcus thermophilus JMCC0003 bacterial mud, and collecting bacterial count of 1×10 11 CFU/g。
2) Preparing composite probiotic microcapsule powder in a mother emulsion:
weighing 1kg of bifidobacterium animalis subspecies i797 powder, 0.5kg of lactobacillus paracasei N1115 powder and 0.5kg of lactobacillus plantarum N3117 powder0.5kg of streptococcus thermophilus JMCC0003 bacterial powder, 1kg of soybean oligosaccharide, 8kg of galactooligosaccharide and 0.5kg of 3' -sialyllactose are put into a mixing tank, stirred at room temperature for 10min and uniformly mixed, and the viable count of each probiotic is kept to be more than or equal to 1 multiplied by 10 10 CFU/g, and the composite probiotic microcapsule powder of the mother emulsion is prepared.
The following are the preparation methods of the parent emulsified composite probiotic microcapsule powders in examples 2-6, respectively, according to the raw material amounts in examples 2-6, the preparation steps are the same as those of example 1, except that each process parameter in each step is different, and the specific different process parameters are shown in the following table:
table 2 list of the different process parameters of examples 2-6
The indexes of the parent emulsified composite probiotic microcapsule powder prepared in examples 1-6 are shown in Table 3:
table 3 product index
EXAMPLE 7 acid and bile salt resistance Properties of the masterbatch emulsified composite probiotic micro-capsule powder
7 parts of low pH culture solution (pH=2.0) and 7 parts of high bile salt culture solution (containing 3%o pig bile salt) which are similar to the gastrointestinal environment of a human body are respectively prepared.
Taking 1g of the mother emulsified composite probiotic microcapsule powder prepared in examples 1-6 and 1g of composite probiotic bacteria respectively, adding 7 parts of 9mL of low pH culture solution which is preheated at 37 ℃ and approximates the gastrointestinal tract environment of a human body respectively, and incubating for 2 hours;
the mother emulsified composite probiotic microcapsule powder and 1g composite probiotic bacterial body prepared in examples 1-6 of 1g were also taken respectively, and added to 7 parts of 9mL high-bile salt culture solution preheated at 37 ℃ respectively, and incubated for 6 h;
after completion of the incubation, colonies of the above 14 parts of the mixture were counted, respectively.
After the completion of the counting, 14 parts of the mixed solution were dispersed by a homogenizer for 60 seconds, and after slowly shaking for 15 minutes, the colony count was performed again on 14 parts of the mixed solution.
TABLE 4 evaluation results of acid and bile salt resistance characteristics
As can be seen from Table 4, compared with the unencapsulated probiotics, the embedding treatment of the mother-emulsified composite probiotic microcapsule powder prepared in examples 1-6 improves the acid and alkali resistance of the probiotics, so that the mother-emulsified composite probiotic microcapsule powder prepared in the invention has a certain acid and alkali resistance and can be better suitable for the human gastrointestinal tract environment.
EXAMPLE 8 Effect of the masterbatch emulsified composite probiotic micro-capsule powder on intestinal Barrier function
The intestinal canal development is extremely important in the growth process of infants, and provides guarantee for infants to absorb essential nutrient substances. Some probiotics are attached in the development process of the intestinal canal of the infant, and the probiotics can maintain the activity of intestinal cells by adjusting the permeability of the intestinal canal, so that the aim of maintaining the tight connection structure among the intestinal cells is fulfilled. Based on this, the present embodiment adopts H 2 O 2 An in vitro Caco-2 cell research model for oxidative damage of intestinal cells is used for evaluating the influence of composite probiotics on the intestinal barrier function of infants.
Preparation of a bacterial suspension of a Complex probiotic mixture of four strains of Bifidobacterium animalis subspecies i797, lactobacillus paracasei N1115, lactobacillus plantarum N3117 and Streptococcus thermophilus JMCC0003 (final total concentration about 1X 10) 8 CFU/well), 6h incubated with the in vitro Caco-2 cell study model of injury, measured transmembrane resistance values at 2h, 4h, 6h, respectively, and relative transmembrane resistance values calculated according to the following formula:
the intercellular tight junction structure is the basis of the intestinal tract mechanical barrier, and in a Caco-2 cell research model of Transwell, if the tight junction structure is damaged, the resistance to ion flow is reduced, and the transmembrane resistance is reduced.
The experimental results, see figure 1, prove that the bacterial suspension of the composite probiotic mixture has a certain maintenance effect on the cell-cell tight connection structure, and can relieve H 2 O 2 Oxidative damage to intestinal cells, and can maintain and protect the tight connection structure of the intestinal cells, and promote the healthy development of the intestinal tracts of infants.
Example 9 oligosaccharide promotes proliferation of intestinal bifidobacteria
50 Kunming male mice were selected and randomly divided into 5 groups: the control group was perfused with 0.2 mL physiological saline every morning; the intervention groups 1-4 were each perfused daily with a physiological saline solution containing a 2% oligosaccharide mixture of 0.2 mL in the morning, followed by 2 weeks of gavage culture and 1 week follow, and the amount of bifidobacteria in the mouse faeces was measured on days 0, 3, 5, 7, 9, 11, 13, 15, 21.
Wherein, the oligosaccharide mixture of the stomach-filling of the intervention group 1-4 groups is added with oligosaccharides with different proportions: the proportion of intervention group 1 was soybean oligosaccharide: galacto-oligosaccharides: 3' sialyllactose = 1:1: 1. the proportion of intervention group 2 was soybean oligosaccharide: galacto-oligosaccharides: 3' sialyllactose = 1:1: 2. the proportion of intervention group 3 was soybean oligosaccharide: galacto-oligosaccharides: 3' sialyllactose = 2:1:2. the proportion of intervention group 4 was soybean oligosaccharide: galacto-oligosaccharides: 3' sialyllactose = 2:2:1.
the oligosaccharide mixture was able to promote proliferation of bifidobacteria in the intestinal tract of mice in the results of the intervention groups 1-4 compared to the control group, as shown in figure 2, after 2 weeks of gastric lavage culture and 1 week of follow-up detection. Wherein, the result of the intervention group 3 is optimal, the adding proportion of the oligosaccharide mixture is soybean oligosaccharide: galacto-oligosaccharides: 3' sialyllactose = 2:1:2.
from this it was demonstrated that the addition of galactooligosaccharides and 3' sialyllactose helps to promote the proliferation of bifidobacteria in the intestinal tract.
EXAMPLE 10 evaluation of the parent emulsified composite probiotic microcapsule powder on early growth and bifidobacterium colonization
30 neonatal C57BL/6 mice were selected and randomly divided into 2 groups: the control group irrigates 20 mu L of physiological saline in the morning each day; the intervention group was gavaged daily for 20 μl of physiological saline containing 10 μg of the complex probiotic microcapsule powder prepared in example 1, and the gavage culture was continued for 2 weeks and followed for 1 week, recording the body mass every 2 days.
The initial body mass was set to 1, and the body mass measured thereafter was a multiple of the initial body mass, and the amount of bifidobacteria in the feces of mice was measured on days 0, 3, 5, 7, 9, 11, 13, 15, 21.
After 2 weeks of gastric lavage culture and 1 week of follow-up detection, the body mass of the intervention group and the control group is continuously increased, the intervention group is faster than the control group, and the content of the intestinal bifidobacteria of the mice in the intervention group is higher than that in the control group as shown in fig. 3 and 4.
From this, it is proved that the composite probiotic microcapsule powder of the mother emulsion can promote the growth of the newborn mice and the growth and colonization of intestinal beneficial bacteria, and has beneficial effects on early growth.
Example 11A method for isolation and purification of Bifidobacterium animalis subspecies Lactobacter i797
The embodiment provides a method for separating and purifying bifidobacterium animalis subspecies i797, which is carried out according to the following steps:
1. collecting a sample
Taking 1g of infant or infant intestinal faeces, then adding the infant or infant intestinal faeces into 9ml of physiological saline, and fully and uniformly mixing to obtain a sample A;
2. sample enrichment
Taking 2mL of sample A, adding the sample A into 100mL of improved MRS liquid culture medium, and carrying out anaerobic culture for 72 hours at 37 ℃ to obtain a culture solution B;
3. bacterial strain isolation and screening
Taking 1ml of culture solution B1, and carrying out 10-time gradient multiplication dilution by using sterile physiological saline with the concentration of 0.9%, wherein the gradient dilution is sequentially carried out for 10 -1 、10 -2 、10 -3 、10 -4 、10 -5 Doubling to obtain bacterial suspension C1 1 ～C1 5 ；
Taking improved MRS (MRS) fastenerAfter the body culture medium is melted, respectively pouring the melted body culture medium into first to fifth culture dishes, and obtaining a culture medium D after cooling and complete solidification 1 ～ D 5 Respectively sucking the bacterial suspension C 1 ～C 5 Each 0.1mL of the solution was applied to the medium D in a one-to-one correspondence 1 ～D 5 Then inverting the flat plate, placing the flat plate in an environment of 37 ℃ for anaerobic culture for 72 hours, and observing the growth condition of bacterial colonies;
after the typical colony of the flat plate appears, selecting a corresponding single colony E according to colony characteristics of standard bifidobacteria and reference related literature pictures;
4. strain purification
Selecting a selected single colony E, streaking and inoculating a single colony E culture to an improved MRS solid culture medium, and culturing for 72 hours in an anaerobic environment at 37 ℃ to obtain a single colony F;
continuously streaking and inoculating the single colony F onto an improved MRS solid culture medium, and culturing for 72 hours in an anaerobic environment at 37 ℃ to obtain a single colony G;
then, continuously streaking and inoculating the single colony G onto an improved MRS solid culture medium, and culturing for 72 hours in an anaerobic environment at 37 ℃ to obtain a pure culture H, namely the strain of the bifidobacterium animalis subspecies i 797;
5. preservation of
Mixing pure culture H with sterile glycerol with the mass fraction of 50% according to the ratio of 1:1, placing into a strain preservation tube, preserving at-70deg.C after mixing, and simultaneously inoculating an improved MRS solid culture medium test tube inclined plane for temporary preservation.
In this example, the improved MRS liquid media feed stock includes: casein peptone, beef extract, yeast extract, glucose, sodium acetate, citric acid diamine, tween-80, K 2 HPO 4 、MgSO 4 ·7H 2 O、MnSO 4 ·7H 2 O, cysteine and distilled water; wherein the casein peptone, beef extract, yeast extract, glucose, sodium acetate, citric acid diamine, tween-80, K 2 HPO 4 、MgSO 4 ·7H 2 O、MnSO 4 ·7H 2 The dosage proportion relation of O, cysteine and distilled water is 10g:10g:5g:20g:5g:2g:1g:2g:0.2g:0.05g:0.5g:1000mL; the modified MRS solid medium was prepared by adding 15% by mass of agar per 1000mL of the modified MRS liquid medium.
EXAMPLE 12 basic bacteriological characteristics of the species Bifidobacterium animalis subspecies lactis i797
This example shows the basic bacteriological characteristics of bifidobacterium animalis subspecies i797, as shown in table 5:
TABLE 5 basic characteristics of bifidobacterium animalis subspecies lactis i797
EXAMPLE 13 sugar fermentation Properties of Bifidobacterium animalis subspecies lactis i797 Strain
This example shows the sugar fermentation characteristics of bifidobacterium animalis subspecies i797 strain in example 1. The experimental method of the sugar fermentation characteristics comprises the following steps: the bifidobacterium animalis subspecies i797 strain is picked up to be inoculated into a sterilized improved MRS liquid culture medium, cultured for 24 hours at 37 ℃, inoculated into a sugar fermentation tube, anaerobically cultured for 48 hours at 37 ℃ and observed for color change. The results of the identification of the sugar fermentation characteristics are shown in Table 6:
TABLE 6 identification of fermentation characteristics of Bifidobacterium animalis subspecies lactis i797 sugar
Note that: "+" indicates fermentation utilization; "-" means not fermentation for use.
The modified MRS liquid medium used in this example was the same as the modified MRS liquid medium of example 11 in composition.
EXAMPLE 14 gastric acid and intestinal fluid tolerance Properties of bifidobacterium animalis subspecies lactis i797 Strain
After 3 generations of the bifidobacterium lactis subspecies i797 strain to be tested is activated, 1mL of the strain is taken and respectively placed in artificial gastric juice with the pH value of 3.0 and subjected to filtration sterilization treatment of 9mL, the strain is evenly vibrated and subjected to anaerobic culture at 37 ℃, and the sample is taken respectively when the culture and the culture are started for 2h, so that the viable count of the strain is measured. Then, the culture solution 1mL after 2h is digested in artificial gastric juice with pH value of 3.0 is inoculated into artificial intestinal juice with pH value of 8.0 which is filtered and sterilized by 9mL respectively, and is continuously cultured at 37 ℃, and the number of viable bacteria is measured at 0h, 4h and 6h respectively.
Control experiments were performed using bifidobacterium BB-12 as a standard strain, and the experimental parameters were the same as those of the bifidobacterium animalis subspecies i797 strain described above.
Survival (%) = (cfu N1/cfu N0) ×100%
Wherein N1 is the number of viable bacteria of 6h treated with artificial digestive juice, and N0 is the number of viable bacteria of 0h treated with artificial digestive juice.
b. Intestinal juice: bile Salts (Difco) 0.9 g/100 mL, adjusting pH to 8.0, filtering and sterilizing for later use.
TABLE 7 simulation of gastric juice intestinal juice tolerance results for bifidobacterium lactis subspecies i797 in animals
Experiments show that BB-12 has stronger gastric acid tolerance and poorer intestinal juice tolerance, while bifidobacterium animalis subspecies i797 has poorer gastric acid tolerance and stronger intestinal juice tolerance. The comprehensive comparison of the bifidobacterium animalis subspecies i797 has better survival rate of simulated digestive juice, and the survival rate reaches 7.4 percent which is better than BB-12.
Sequence listing
<110> Shijiujun Le Baoru company Limited
<120> composite probiotic microcapsule powder for mother emulsification, and preparation method and application thereof
<130> 20200402
<150> 2019112636449
<151> 2019-12-11
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1411
<212> DNA
<213> Bifidobacterium animalis subsp lactis
<400> 1
acggctcccc cacaagggtc gggccaccgg cttcgggtgc tacccacttt catgacttga 60
cgggcggtgt gtacaaggcc cgggaacgca ttcaccgcgg cgttgctgat ccgcgattac 120
tagcgactcc gccttcacgc agtcgagttg cagactgcga tccgaactga gaccggtttt 180
cagcgatccg ccccacgtca ccgtgtcgca ccgcgttgta ccggccattg tagcatgcgt 240
gaagccctgg acgtaagggg catgatgatc tgacgtcatc cccaccttcc tccgagttga 300
ccccggcggt cccacatgag ttcccggcat cacccgctgg caacatgcgg cgagggttgc 360
gctcgttgcg ggacttaacc caacatctca cgacacgagc tgacgacgac catgcaccac 420
ctgtgaaccg gccccgaagg gaaaccgtgt ctccacggcg atccggcaca tgtcaagccc 480
aggtaaggtt cttcgcgttg catcgaatta atccgcatgc tccgccgctt gtgcgggccc 540
ccgtcaattt ctttgagttt tagccttgcg gccgtactcc ccaggcggga tgcttaacgc 600
gttggctccg acacgggacc cgtggaaagg gccccacatc cagcatccac cgtttacggc 660
gtggactacc agggtatcta atcctgttcg ctccccacgc tttcgctcct cagcgtcagt 720
gacggcccag agacctgcct tcgccattgg tgttcttccc gatatctaca cattccaccg 780
ttacaccggg aattccagtc tcccctaccg cactccagcc cgcccgtacc cggcgcagat 840
ccaccgttag gcgatggact ttcacaccgg acgcgacgaa ccgcctacga gccctttacg 900
cccaataaat ccggataacg ctcgcaccct acgtattacc gcggctgctg gcacgtagtt 960
agccggtgct tattcgaaca atccactcaa cacggccgaa accgtgcctt gcccttgaac 1020
aaaagcggtt tacaacccga aggcctccat cccgcacgcg gcgtcgctgc atcaggcttg 1080
cgcccattgt gcaatattcc ccactgctgc ctcccgtagg agtctgggcc gtatctcagt 1140
cccaatgtgg ccggtcaccc tctcaggccg gctacccgtc aacgccttgg tgggccatca 1200
ccccgccaac aagctgatag gacgcgaccc catcccatgc cgcaaaagca tttcccaccc 1260
caccatgcga tggagcggag catccggtat taccacccgt ttccaggagc tattccggtg 1320
cacagggcag gttggtcacg cattactcac ccgttcgcca ctctcacccg acagcaagct 1380
gccagggatc ccgttcgact gcatgtgtaa g 1411
<210> 2
<211> 994
<212> DNA
<213> Bifidobacterium animalis subsp lactis
<400> 2
ggatctcgat gagagcagcg tggtatcacc atcaacattg cccacatcga gtaccagacg 60
gccaagcgtc actacgccca cgtcgactgc ccgggccacg ccgacttcgt gaagaacatg 120
atcaccggcg ctgcccagat ggatggcgcc atcctcgttg tggccgccac cgacggcccg 180
atggcccaga cccgcgagca cgtgctgctc gcccgtcagg tcggcgtccc gaagatcctc 240
gtcgctctga acaagtgcga tatggtcgat gacgaagagc tcatcgagct cgtcgaagaa 300
gaggtccgcg acctcctcga cgagaacggc ttcgaccgcg actgcccggt cgtgcacacc 360
tccgcttacg gcgctctgca tgacgacgct cccggatcac gacaagtggg ttgccaccat 420
caaggagctc atggacgacg tcgacgagta catcccgacc ccggtccacg acctcgacaa 480
gccgttcctg atgccgatcg aggacgtctt caccatctcc ggccgtggca ccgtcgtcac 540
cggtcgtgtc gagcgcggca agctgccgat caacacgaac gtcgagatcg tcggcatccg 600
cccgacccag accaccaccg tcacctccat cgagaccttc cacaagcaga tggatgagtg 660
cgaggccggc gacaacaccg gtctgctgct ccgcggcatc aaccgcaccg acgtcgagcg 720
tggccaggtc gtggctgctc cgggttcggt caccccgcac accaagttcg aaggcgaagt 780
ctacgtcctt accaaggatg agggcggccg tcactcgccg ttcttctcga actaccgtcc 840
gcagttctac ttccgcacca ccgacgtcac cggcgtcatc acgctgccgg aaggcgtcga 900
gatggttcag cctggcgatc acgcgacctt cacggttgag ctgatccagc cgatcgctat 960
ggaagagggc ttcaccttcc cagtgcttga aggc 994
Claims (9)
1. A breast milk compound probiotics microcapsule powder is characterized in that:
the composite probiotic microcapsule powder is prepared from the following raw materials in parts by weight: 1-5 parts of soybean oligosaccharide, 5-10 parts of galactooligosaccharide, 0.1-2 parts of 3' -sialyllactose, 5-15 parts of maltodextrin, 5-10 parts of whey protein powder, 1-3 parts of sodium alginate, 1-5 parts of gelatin, 0.1-3 parts of glycerin, 1-10 parts of bifidobacterium animalis subspecies i797 bacterial mud, 0.5-5 parts of lactobacillus paracasei N1115 bacterial mud, 0.5-5 parts of lactobacillus plantarum N3117 bacterial mud and 0.5-5 parts of streptococcus thermophilus JMCC0003 bacterial mud, wherein the four bacterial mud respectively contain corresponding probiotics not less than 1 multiplied by 10 11 CFU/g；
The bifidobacterium animalis subspecies i797 deposit No.: CGMCC No.18403, the preservation number of the lactobacillus paracasei N1115 is: CGMCC No.4691, the preservation number of the lactobacillus plantarum N3117 is: CGMCC No.10133, and the preservation number of the streptococcus thermophilus JMCC0003 is: CGMCC No. 6674.
2. The mother-emulsified composite probiotic microcapsule powder according to claim 1, wherein the mother-emulsified composite probiotic microcapsule powder contains bifidobacterium animalis subspecies i797 not less than 1 x 10 10 CFU/g, lactobacillus paracasei N1115 is more than or equal to 1X 10 10 CFU/g, lactobacillus plantarum N3117 is more than or equal to 1X 10 10 CFU/g and streptococcus thermophilus JCCC 0003 is more than or equal to 1 multiplied by 10 10 CFU/g。
3. The method for preparing the parent emulsified composite probiotic microcapsule powder according to claim 1 or 2, characterized in that the method comprises the following steps performed in sequence:
1) Preparation of bacterial powder
The preparation method comprises the steps of preparing bifidobacterium animalis subspecies i797 powder, lactobacillus paracasei N1115 powder, lactobacillus plantarum N3117 powder and streptococcus thermophilus JCCC 0003 powder, wherein the powder is prepared by the following steps of:
11 Mixing maltodextrin, whey protein powder, sodium alginate, gelatin and glycerol to obtain a mixture A;
12 Adding the mixture A into purified water, hydrating and dissolving, homogenizing, and sterilizing to obtain a sterile protective agent B;
13 Taking bacterial mud of corresponding probiotics, respectively and uniformly mixing with the aseptic protective agent B, freeze-drying, crushing and sieving to obtain bacterial powder of the corresponding probiotics;
2) Preparing composite probiotic microcapsule powder in a mother emulsion:
and uniformly mixing the bacterial powder of the four probiotics, namely, the bifidobacterium animalis subspecies i797 bacterial powder, the lactobacillus paracasei N1115 bacterial powder, the lactobacillus plantarum N3117 bacterial powder and the streptococcus thermophilus JMCC0003 bacterial powder, with soybean oligosaccharide, galactooligosaccharide and 3' -sialyllactose to obtain the composite probiotic microcapsule powder for mother emulsification.
4. The method for preparing the composite probiotic microcapsule powder for mother emulsification according to claim 3, wherein each bacterial sludge is prepared by fermenting corresponding probiotics until the bacterial count is more than or equal to 1 multiplied by 10 11 After CFU/mL, the bacterial liquid is collected and centrifuged to obtain the bacterial liquid.
5. The method for preparing the composite probiotic microcapsule powder for mother emulsification according to claim 4, wherein washing and centrifugation are performed after each bacterial sludge is prepared.
6. The method for preparing the parent emulsified composite probiotic microcapsule powder according to claim 5, wherein the washing is 1-2 times with sterile physiological saline;
the fermentation temperature is 30-42 ℃, and the fermentation time is 36-48 h;
the rotational speed of the centrifugation is 4000-6000 rpm, and the time of the centrifugation is 8-15 min.
7. The method for preparing the composite probiotic microcapsule powder emulsified by a mother according to claim 3,
in the step 1), the temperature of hydration and dissolution is 35-40 ℃;
the homogenizing temperature is 60-65 ℃;
the sterilization temperature is 110-121 ℃, and the sterilization time is 20-25min;
in the step 2), the mixing is carried out for 10-15min.
8. The method for preparing the parent emulsified composite probiotic microcapsule powder according to any one of claims 4 to 7, wherein in step 1), the weight ratio of each bacterial sludge to the sterility protectant B is 1:1-20;
the grain diameter of each bacterial powder is less than or equal to 40 meshes;
in the step 2), the viable count of each probiotic is maintained to be more than or equal to 1 multiplied by 10 during the mixing process 10 CFU/g。
9. Use of the parent emulsified composite probiotic micro-capsule powder according to claim 1 or 2, characterized in that said parent emulsified composite probiotic micro-capsule powder is intended for consumption alone or in combination with infant formula.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911263644.9A CN110959867A (en) | 2019-12-11 | 2019-12-11 | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof |
| CN2019112636449 | 2019-12-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111480849A CN111480849A (en) | 2020-08-04 |
| CN111480849B true CN111480849B (en) | 2023-05-02 |
Family
ID=70033716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911263644.9A Withdrawn CN110959867A (en) | 2019-12-11 | 2019-12-11 | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof |
| CN202010258804.7A Active CN111480849B (en) | 2019-12-11 | 2020-04-03 | Composite probiotic microcapsule powder for mother emulsification and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911263644.9A Withdrawn CN110959867A (en) | 2019-12-11 | 2019-12-11 | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110959867A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197311B (en) * | 2020-07-03 | 2023-06-23 | 内蒙古蒙牛乳业（集团）股份有限公司 | Lactic acid bacteria composition and preparation method thereof |
| CN112006208A (en) * | 2020-08-14 | 2020-12-01 | 新食代布丁(上海)智能科技有限公司 | Composite probiotic powder solid beverage and preparation method thereof |
| US20240000868A1 (en) * | 2020-11-16 | 2024-01-04 | Inner Mongolia Yili Industrial Group Co., Ltd. | Composition Containing Bifidobacterium Lactis and Human Milk Oligosaccharides and Application Thereof |
| CN115251393B (en) * | 2022-07-05 | 2024-02-27 | 上海菌小宝健康科技有限公司 | Probiotic microcapsule for improving intestinal flora and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109601620A (en) * | 2018-11-21 | 2019-04-12 | 石家庄君乐宝乳业有限公司 | Acidified milk and preparation method thereof containing lactobacillus plantarum N3117 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104719887A (en) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | Composite probiotic powder for conditioning intestinal tract flora |
| CN107752040A (en) * | 2017-11-27 | 2018-03-06 | 内蒙古普泽生物制品有限责任公司 | A kind of compound probiotic powder preparation for promoting infant's immunity of organisms and preparation method thereof |
| CN108048349B (en) * | 2017-12-15 | 2020-08-28 | 石家庄君乐宝乳业有限公司 | Preparation method and application of lactobacillus paracasei N1115 embedded bacteria powder |
| CN110506793A (en) * | 2019-09-23 | 2019-11-29 | 石家庄君乐宝乳业有限公司 | Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof |
-
2019
- 2019-12-11 CN CN201911263644.9A patent/CN110959867A/en not_active Withdrawn
-
2020
- 2020-04-03 CN CN202010258804.7A patent/CN111480849B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109601620A (en) * | 2018-11-21 | 2019-04-12 | 石家庄君乐宝乳业有限公司 | Acidified milk and preparation method thereof containing lactobacillus plantarum N3117 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110959867A (en) | 2020-04-07 |
| CN111480849A (en) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111480849B (en) | Composite probiotic microcapsule powder for mother emulsification and preparation method and application thereof | |
| CN111484957B (en) | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof | |
| CN101260377B (en) | Animal bifidobacteria and use thereof | |
| CN114854643B (en) | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof | |
| CN103893214B (en) | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder | |
| CN112870233A (en) | Composition containing bifidobacterium lactis and breast milk oligosaccharide and application thereof | |
| CN112869170B (en) | Probiotics prebiotic nutritional composition capable of improving gastrointestinal tract immunity and application | |
| CN114381411B (en) | Lactococcus lactis JYLL-60 and application thereof in preparation of product for improving immunity | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN112515170A (en) | Bifidobacterium lactis and prebiotics composition for improving gastrointestinal immunity and application thereof | |
| CN112869168A (en) | Probiotics prebiotics composition capable of improving gastrointestinal tract immunity and application thereof | |
| CN110106119A (en) | The Lactobacillus rhamnosus M9 of one plant of isolated from mother's milk and its application | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| CN112544721A (en) | Milk tablet for promoting growth of vital essence and preparation method thereof | |
| CN116814501B (en) | Bifidobacterium longum subspecies capable of relieving obesity and application thereof | |
| WO2022110281A1 (en) | Bifidobacterium bifidum i771, separation and purification method therefor, and application thereof | |
| CN115094012A (en) | Preparation method and application of bacillus coagulans BC-HYC strain microbial inoculum | |
| CN111528283A (en) | Application of lactobacillus rhamnosus X253 with anti-fatigue effect and capability of improving body fatigue tolerance | |
| CN113616715B (en) | Fermented traditional Chinese medicine oral liquid for treating piglet diarrhea and improving intestinal flora thereof | |
| CN117467581B (en) | Pediococcus acidilactici King73 capable of improving canine immunity and application thereof | |
| CN110438042A (en) | One plant of bifidobacterium longum and its application | |
| CN110623066A (en) | Composite probiotic product and preparation method thereof | |
| CN113679048A (en) | High-activity probiotic freeze-dried powder for adjusting balance of intestinal flora of infants | |
| CN113512514A (en) | Lactococcus lactis with depression improving effect and application thereof | |
| CN116286458B (en) | Lactobacillus plantarum LZ010 capable of reducing blood pressure and blood fat and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 050000 No. 68 stone Copper Road, Hebei, Shijiazhuang Applicant after: JUNLEBAO Dairy Group Co.,Ltd. Address before: 050000 No. 68 stone Copper Road, Hebei, Shijiazhuang Applicant before: THE SHIJIAZHUANG JUNLEBAO DAIRY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 050000 No. 68 stone Copper Road, Hebei, Shijiazhuang Patentee after: Junlebao Dairy Group Co.,Ltd. Country or region after: China Address before: 050000 No. 68 stone Copper Road, Hebei, Shijiazhuang Patentee before: JUNLEBAO Dairy Group Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |